Asset Management One Co. Ltd. Purchases 9,237 Shares of DexCom, Inc. $DXCM

Asset Management One Co. Ltd. increased its position in DexCom, Inc. (NASDAQ:DXCM) by 3.6% during the third quarter, according to its most recent Form 13F filing with the SEC. The fund owned 264,022 shares of the medical device company’s stock after buying an additional 9,237 shares during the period. Asset Management One Co. Ltd. owned 0.07% of DexCom worth $17,766,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in the business. Vanguard Group Inc. grew its position in DexCom by 1.8% in the second quarter. Vanguard Group Inc. now owns 48,322,405 shares of the medical device company’s stock worth $4,218,063,000 after acquiring an additional 866,506 shares in the last quarter. Jennison Associates LLC lifted its stake in shares of DexCom by 9.4% in the 2nd quarter. Jennison Associates LLC now owns 11,517,546 shares of the medical device company’s stock valued at $1,005,367,000 after purchasing an additional 994,300 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of DexCom by 3.4% in the 2nd quarter. Geode Capital Management LLC now owns 10,766,356 shares of the medical device company’s stock valued at $936,100,000 after purchasing an additional 358,617 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC boosted its holdings in DexCom by 22.6% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 10,123,525 shares of the medical device company’s stock worth $691,336,000 after purchasing an additional 1,868,241 shares in the last quarter. Finally, Massachusetts Financial Services Co. MA boosted its holdings in DexCom by 106.8% in the second quarter. Massachusetts Financial Services Co. MA now owns 6,605,687 shares of the medical device company’s stock worth $576,610,000 after purchasing an additional 3,410,858 shares in the last quarter. Institutional investors own 97.75% of the company’s stock.

Insiders Place Their Bets

In other news, Director Bridgette P. Heller sold 1,012 shares of the business’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $58.07, for a total transaction of $58,766.84. Following the transaction, the director owned 27,031 shares in the company, valued at approximately $1,569,690.17. The trade was a 3.61% decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, COO Jacob Steven Leach bought 18,200 shares of DexCom stock in a transaction that occurred on Monday, November 10th. The stock was bought at an average price of $55.04 per share, with a total value of $1,001,728.00. Following the purchase, the chief operating officer owned 331,697 shares of the company’s stock, valued at $18,256,602.88. This trade represents a 5.81% increase in their position. The SEC filing for this purchase provides additional information. Insiders have sold 7,866 shares of company stock worth $448,177 in the last ninety days. Insiders own 0.32% of the company’s stock.

Analyst Upgrades and Downgrades

DXCM has been the subject of a number of analyst reports. Evercore ISI assumed coverage on DexCom in a research report on Tuesday, November 25th. They issued an “in-line” rating and a $68.00 price target for the company. Morgan Stanley raised DexCom from an “equal weight” rating to an “overweight” rating and raised their price objective for the company from $63.00 to $75.00 in a research note on Tuesday, December 2nd. Canaccord Genuity Group set a $99.00 target price on DexCom and gave the stock a “buy” rating in a research report on Friday, October 31st. Argus lowered their price target on DexCom from $100.00 to $90.00 and set a “buy” rating on the stock in a report on Friday, November 7th. Finally, Royal Bank Of Canada reduced their price objective on shares of DexCom from $100.00 to $85.00 and set an “outperform” rating for the company in a research note on Friday, October 31st. Three analysts have rated the stock with a Strong Buy rating, nineteen have assigned a Buy rating, five have issued a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, DexCom has a consensus rating of “Moderate Buy” and an average price target of $86.61.

DexCom Stock Performance

Shares of NASDAQ DXCM opened at $67.65 on Tuesday. DexCom, Inc. has a 12 month low of $54.11 and a 12 month high of $93.25. The company has a market cap of $26.38 billion, a P/E ratio of 37.58, a P/E/G ratio of 1.20 and a beta of 1.48. The business’s 50 day moving average is $63.68 and its two-hundred day moving average is $72.40. The company has a quick ratio of 1.38, a current ratio of 1.56 and a debt-to-equity ratio of 0.45.

DexCom (NASDAQ:DXCM) last posted its quarterly earnings data on Thursday, October 30th. The medical device company reported $0.61 earnings per share for the quarter, beating the consensus estimate of $0.57 by $0.04. DexCom had a return on equity of 30.65% and a net margin of 15.96%.The company had revenue of $1.21 billion during the quarter, compared to analysts’ expectations of $1.18 billion. During the same period in the prior year, the business earned $0.45 earnings per share. DexCom’s revenue for the quarter was up 21.6% compared to the same quarter last year. On average, equities analysts expect that DexCom, Inc. will post 2.03 EPS for the current year.

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.